Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells

被引:24
|
作者
Yamashita, Naoya [1 ]
Saito, Nao [1 ]
Zhao, Shuai [1 ]
Terai, Kensuke [2 ,3 ]
Hiruta, Nobuyuki [2 ,3 ]
Park, Youngjin [4 ,5 ]
Bujo, Hideaki [2 ]
Nemoto, Kiyomitsu [1 ]
Kanno, Yuichiro [5 ]
机构
[1] Toho Univ, Fac Pharmaceut Sci, Dept Mol Toxicol, Miyama 2-2-1, Funabashi, Chiba 2748510, Japan
[2] Toho Univ, Sakura Med Ctr, Dept Clin Lab & Expt Res Med, Shimoshizu 564-1, Sakura, Chiba 2858741, Japan
[3] Toho Univ, Sakura Med Ctr, Dept Surg Pathol, Shimoshizu 564-1, Sakura, Chiba 2858741, Japan
[4] Toho Univ, Sakura Med Ctr, Dept Surg, Shimoshizu 564-1, Sakura, Chiba 2858741, Japan
[5] Tohoku Med & Pharmaceut Univ, Dept Breast & Endocrine Surg, Fukumuro 1-15-1, Sendai, Miyagi 9838536, Japan
基金
日本学术振兴会;
关键词
Breast cancer; AhR; Heregulin; HER2; HER3; MAMMOSPHERE FORMATION; EXPRESSION; REVEALS; TRANSCRIPTION; METASTASIS; ACTIVATION; NETWORK; GROWTH; ERBB3; HER2;
D O I
10.1016/j.yexcr.2018.02.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HER2 overexpression accounts for approximately 15-20% of all breast cancers. We have shown that HER2 overexpression leads to elevated expression of the aryl hydrocarbon receptor (AhR) in breast cancer cells. In this study, firstly, we showed that AhR expression was up-regulated by treatment with the HER3 ligand heregulin (HRG) in HER2-overexpressing breast cancer cell lines. Induction of AhR was mediated by transcriptional activation of the region of AhR promoter corresponding to -190 to -100 bp. In addition, HRG treatment elicited nuclear translocation of AhR. To investigate the role of AhR in HRG-HER2/HER3 signaling in HER2-overexpressing cells, we established AhR knockout (KO) HER2-overexpressing cells to perform wound-healing assays. HRG-induced cell migration was markedly attenuated by AhR KO. HRG-induced cell migration was associated with increased expression of the inflammatory cytokines interleukin (IL)-6 and IL-8 in wild type cells, but not in AhR KO cells. These results elucidate that AhR is an important factor for the malignancy in HER2-overexpressing breast cancers.
引用
收藏
页码:34 / 40
页数:7
相关论文
共 50 条
  • [1] AhR plays an important role in heregulin-induced cell migration in HER2-overexpressing breast cancer cells
    Yamashita, Naoya
    Saito, Nao
    Nemoto, Kiyomitsu
    Degawa, Masakuni
    Kanno, Yuichiro
    CANCER SCIENCE, 2018, 109 : 456 - 456
  • [2] Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer
    Joselina Magali Mondaca
    Ana Carla Castro Guijarro
    Marina Inés Flamini
    Angel Matias Sanchez
    Breast Cancer Research and Treatment, 2021, 186 : 363 - 377
  • [3] Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+breast cancer
    Magali Mondaca, Joselina
    Castro Guijarro, Ana Carla
    Ines Flamini, Marina
    Matias Sanchez, Angel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (02) : 363 - 377
  • [4] Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
    Shattuck, David L.
    Miller, Jamie K.
    Carraway, Kermit L., III
    Sweeney, Colleen
    CANCER RESEARCH, 2008, 68 (05) : 1471 - 1477
  • [5] Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance
    Liu, Dan
    Shi, Ming
    Duan, Chenyang
    Chen, Hongyu
    Hu, Yabin
    Yang, Zhengyan
    Duan, Huijun
    Guo, Ning
    MOLECULAR IMMUNOLOGY, 2013, 56 (1-2) : 104 - 112
  • [6] Treatment of HER2-overexpressing breast cancer
    Baselga, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 36 - 40
  • [7] Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms
    Le, XF
    McWatters, A
    Wiener, J
    Wu, JY
    Mills, GB
    Bast, RC
    CLINICAL CANCER RESEARCH, 2000, 6 (01) : 260 - 270
  • [8] Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
    Kang, Jeffrey C.
    Poovassery, Jayakumar S.
    Bansal, Pankaj
    You, Sungyong
    Manjarres, Isabel M.
    Ober, Raimund J.
    Ward, E. Sally
    MABS, 2014, 6 (02) : 340 - 353
  • [9] Lapatinib for the treatment of HER2-overexpressing breast cancer
    Jones, J.
    Takeda, A.
    Picot, J.
    von Keyserlingk, C.
    Clegg, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 1 - 6
  • [10] Pyrotinib enhances the radiosensitivity of HER2-overexpressing gastric and breast cancer cells
    Huang, Tingting
    Luo, Xiaoxiao
    Wu, Bili
    Peng, Ping
    Dai, Yuhong
    Hu, Guangyuan
    Qiu, Hong
    Yuan, Xianglin
    ONCOLOGY REPORTS, 2020, 44 (06) : 2634 - 2644